Advertisement
Advertisement
U.S. markets close in 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.7457+0.0107 (+1.46%)
As of 03:44PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.7350
Open0.7373
Bid0.7301 x 1300
Ask0.7346 x 1400
Day's Range0.7000 - 0.7460
52 Week Range0.5800 - 4.1500
Volume219,230
Avg. Volume494,274
Market Cap37.831M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-1.4600
Earnings DateSep 21, 2022 - Sep 26, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGTC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Applied Genetic Technologies Co
    RGNX: Rating decreased to a SELLREGENXBIO INC has an Investment Rating of SELL; a target price of $24.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    AGTC Announces Key Appointments to Leadership Team

    AGTC Welcomes Eduardo Jacobo as the Sr. Vice President of GMP Manufacturing and Dr. David Jacobs as the Sr. Vice President of Clinical Research and Medical AffairsGAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited

  • GlobeNewswire

    AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based

  • GlobeNewswire

    AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the formation of a scientific advisory board (SAB) comprised of leading experts in age-related macular degeneration (AMD). The S

Advertisement
Advertisement